Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2026 09:10 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
April 23, 2026 09:02 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxan
April 23, 2026 09:01 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial

ACAPELLA is the European multicenter clinical trial evaluating Alpha DaRT alpha-emitter radiotherapeutics combined with capecitabine for inoperable LAPC patients who have completed first-line...
July 25, 2023 05:55 ET | Source: CMI

Alpha Emitter Market Anticipated to Reach $2,649.1 Million, Globally, by 2030 at 10.3% CAGR: Coherent Market Insights (CMI)

Burlingame, July 25, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global alpha emitter market is estimated to be valued at US$ 1,311.0 million in 2023 and is expected to...